Quantum BioPharma Ltd. Cash Flow-to-Debt Ratio
Quantum BioPharma Ltd. cash flow-to-debt ratio. Quantum BioPharma Ltd. (QNTM) has a Cash Flow-to-Debt Ratio of -0.21x as of June 2026, meaning its operating cash flow of $-1.74 Million could theoretically repay 0% of its total liabilities ($8.29 Million) in one year. Check earnings quality score of Quantum BioPharma Ltd. to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Quantum BioPharma Ltd. (2015–2025)
Cash flow-to-debt ratio of Quantum BioPharma Ltd. from 2015 to 2025. Historical debt coverage capacity for Quantum BioPharma Ltd. across 11 annual periods. Check how aggressively does Quantum BioPharma Ltd. reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Quantum BioPharma Ltd. Cash Flow-to-Debt Ratio by Year (2015–2025)
Quantum BioPharma Ltd. cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Quantum BioPharma Ltd.. For the full cash flow conversion analysis, see Quantum BioPharma Ltd. operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.39x | $-8.38 Million | $6.05 Million | ▼ -34.6% |
| 2024 | -1.03x | $-6.88 Million | $6.68 Million | ▲ +56.6% |
| 2023 | -2.37x | $-10.83 Million | $4.57 Million | ▲ +34.1% |
| 2022 | -3.60x | $-28.33 Million | $7.87 Million | ▼ -53.3% |
| 2021 | -2.35x | $-20.75 Million | $8.83 Million | ▲ +30.5% |
| 2020 | -3.38x | $-19.13 Million | $5.66 Million | ▼ -71.1% |
| 2019 | -1.98x | $-13.71 Million | $6.94 Million | ▲ +81.4% |
| 2018 | -10.60x | $-13.58 Million | $1.28 Million | ▼ -8857.2% |
| 2017 | -0.12x | $-119.18K | $1.01 Million | ▲ +73.3% |
| 2016 | -0.44x | $-27.24K | $61.43K | ▼ -42203.3% |
| 2015 | 0.00x | $-63.44 | $60.53K | — |